{'fraction_non_alphanumeric': 0.01366120218579235, 'fraction_numerical': 0.009107468123861567, 'mean_word_length': 5.464705882352941, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Effectiveness of edaravone in patients with minor ischemic stroke and hyperglycemia

It has been reported that hyperglycemia associated with neurological deterioration in patients with acute ischemic stroke. We evaluated the effectiveness of edaravone in minor stroke patients with hyperglycemia. We retrospectively analyzed 32 consecutive acute stroke patients with hyperglycemia of over 200mg (cid:1) d l and neurological symptoms of between 1 and 4 on the National Institutes of Health Stroke Scale (NIHSS) score. We investigated which factors were associated with a good outcome of 0 or 1 on the modified Rankin Scale at hospital discharge. A good outcome was significantly related to a lower score on the NIHSS at admission, the administration of edaravone, and abnormality of serum creatinine. Multiple logistic regression analysis demon-strated a significant association of both a low score on the NIHSS and the administration of edaravone with a good outcome. The results obtained indicated that edaravone might improve the neurological symptoms in minor stroke patients with hyperglycemia.